J&J bolsters Rybrevant-Lazcluze's case against AZ's Tagrisso with survival analysis

Johnson & Johnson’s newly FDA-approved lung cancer combination of Rybrevant and Lazcluze is inching ever closer to a statistically significant survival showing, which could help it better challenge AstraZeneca’s Tagrisso.